Cancer diagnostics company Pacific Edge (ASX:PEB) has released its investor update for the three months ended December 2025, highlighting key strategic developments aimed at reinstating Medicare coverage for its Cxbladder tests and reporting on test volumes processed through its laboratories.
It also notes that Kaiser Permanente’s Real World Evidence study demonstrating Cxbladder Triage's clinical utility has been accepted for publication in Urology Practice, potentially strengthening Pacific Edge’s position at the CAC.
The company reported ongoing progress in Medicare appeals for Cxbladder Triage tests denied reimbursement following the Genetic Testing for Oncology LCD (L39365) that ended coverage.
The first of four hearings is scheduled for Feb. 24, immediately after the CAC meeting.